Showing results (41-50 of 129) with videos related to
Sort By:
Pageof 13
American Journal of Nephrology|October 26, 2013
Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysisTill Koch, Stefanie Derer, Matthias Staudinger, et al.Frontiers in Immunology|September 29, 2025
Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancerHans-Heinrich Oberg, Malte Deseke, Steffen Krohn, et al.British Journal of Haematology|April 14, 2006
A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cellsMichael Schwemmlein, Matthias Peipp, Karin Barbin, et al.Haematologica|September 24, 2016
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growthRenate Burger, Andreas Günther, Katja Klausz, et al.Mabs|February 5, 2014
Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicityStefanie Derer, Pia Glorius, Martin Schlaeth, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2015
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor CellsStefanie Derer, Michael Cossham, Thies Rösner, et al.Cancer Science|March 25, 2010
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cellsMartin Schlaeth, Sven Berger, Stefanie Derer, et al.Haematologica|June 6, 2020
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapyKatja Klausz, Michael Cieker, Christian Kellner, et al.Blood|February 7, 2004
Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allograftsPeter Lang, Karin Barbin, Tobias Feuchtinger, et al.Journal of Leukocyte Biology|December 14, 2019
Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumorsHans-Heinrich Oberg, Lisa Janitschke, Vjola Sulaj, et al.Pageof 13